1. FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019) Authors: Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; Pinilla‐Ibarz, J.; Opat, S.; Sivcheva, L.; Le Dû, K.; Fogliatto, L.M.; Utoft Niemann, C.; Weinkove, R.; Robinson, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL. (12th June 2019) Authors: Langerbeins, P.; Bahlo, J.; Rhein, C.; Gerwin, H.; Cramer, P.; Fürstenau, M.; Al‐Sawaf, O.; von Tresckow, J.; Fink, A.M.; Kreuzer, K.; Vehling‐Kaiser, U.; Tausch, E.; Müller, L.; Eckart, M.; Schlag, R.; Freier, W.; Gaska, T.; Balser, C.; Reiser, M.; Stauch, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY. (17th June 2021) Authors: Al‐Sawaf, O.; Zhang, C.; Robrecht, S.; Tandon, M.; Panchal, A.; Fink, A.‐M.; Tausch, E.; Ritgen, M.; Kreuzer, K.‐A.; Kim, S.; Wendtner, C.; Eichhorst, B.; Stilgenbauer, S.; Jiang, Y.; Hallek, M.; Fischer, K. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗